Dr. Meagan Anne Jacoby, MD

Dr. Jacoby practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Jacoby's NPI, 1447371786, was assigned on April 3, 2007. Dr. Jacoby graduated from Washington University School of Medicine in 2005. Dr. Jacoby holds Missouri license 2011009915.

Dr. Jacoby's primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Jacoby also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Jacoby's primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Jacoby is also affiliated with Christian Hospital. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Jacoby to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jacoby practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Jacoby's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Jacoby is licensed in Missouri.

CMS data shows 1,412 Medicare services from Dr. Jacoby across 12 procedure codes in 2024, for 247 Medicare patients. Medicare paid $64,722 for them.

CMS counts 247 Medicare patients who saw Dr. Jacoby in 2024. The largest group is 65 to 74, with 125 patients. 73% of them have high blood pressure, and 70% have high cholesterol. 11% are also on Medicaid. Their average risk score is 3.38, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jacoby's median patient age at 71, with 44% women.

In 2024, Dr. Jacoby wrote 1,286 Medicare Part D claims for 85 patients. 87% of them were for generic drugs. CMS names the drug for 958 of them, across 28 drugs with 11 or more claims each, at $1,130,659 in total drug cost. In 2023, CMS named 1,008 claims across 36 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Jacoby for performance year 2024, reported as part of a group. Dr. Jacoby accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 49 papers to Dr. Jacoby, published from 2013 to 2024. 2021 was the busiest year, with 8. The most frequent topics are Leukemia, Myeloid, Acute, Myelodysplastic Syndromes and Azacitidine. Dr. Jacoby has published most often in Blood. Dr. Jacoby's most frequent co-authors are John F. Dipersio, MD, Geoffrey Lim Uy, MD and Amanda Fishback Cashen, MD.

Dmand AI links Dr. Jacoby to 10 clinical trials, 4 of them phase 1 studies. 5 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Myelodysplastic Syndromes and Leukemia, Myeloid. Washington University School of Medicine sponsors the most, 10.

CMS Open Payments shows 24 general payments to Dr. Jacoby from 7 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 88% of the total. Novo Nordisk AS paid the most, $36,690. It also lists 26 research payments totaling $21,825 from 2018 to 2019.

Dr. Jacoby graduated from Washington University School of Medicine in 2005.